BioSpace News Archive

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that management will present at the LD 500 Virtual Conference, hosted by LD Micro and taking place virtually September 1 – 4, 2020.

IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that it has granted Exeltis Healthcare, S.L. (“Exeltis”) an exclusive license to manufacture and commercialize RIZAPORT®, a unique oral thin film for the treatment of acute migraines, in the European Union (“EU”).

NovaSignal Corp., a medical technology and data company specializing in assessing cerebral blood flow, announced today that its board of directors has appointed John M. Donovan as an independent director, effective Wednesday, August 26t

ATCC, the world’s premier biological materials management and standards organization, announced it has promoted Teri Sellars to the position of Vice President, Human Resources and Chief People Officer.

Wenzel Spine, Inc., a medical technology company focused on providing minimally invasive solutions for the treatment of spinal disorders, today announced that it has completed the acquisition of Statera Spine, a pre-operative diagnostics and quantitative data software solution that improves treatment decisions for spine patients. Statera Spine is a software enabled spine imaging analytics company dedicated to providin

- New U.S. Patent No. 10,730,826 provides additional composition of matter protection for atuzaginstat (COR388) - The ‘826 patent extends the patent term for atuzaginstat to 2037, with a possible patent term extension of up to an additional five years

Halberd Corp. (OTC PINK:HALB) is pleased to announce the successful completion of its search for a major research university partner

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from GlaxoSmithKline (GSK) triggered by European Commission conditional marketing authorisation for GSK’s BLENREP™ (belantamab mafodotin), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics’ proprietary technology. BLENREP was developed and will be commercialized by GSK. In

DURECT Corporation (Nasdaq: DRRX) today announced the presentation of pharmacokinetic (PK) data from a Phase 2a study of DUR-928 in alcoholic hepatitis (AH) at the Digital International Liver Congress™ 2020 (EASL), taking place on August 27-29.

Canadian oral hygiene brand, Oral Science has been creating trusted products that sell to both customers and oral health professionals for more than sixteen years.